Last 12 months
Inside the activity.
1 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 1 | 1 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 10:50 UTC |
Zuegel MartinDirector · Interim CEO
|
GrantShare Option (right to buy) · Derivative | 77,778 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001651625-26-000010 · primary_doc.xml · derivative · entry 2 Zuegel Martin · CIK 0001484988 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,778 Underlying: Common Share · 77,778 shares Expires 2036-06-10 F3 · derivative.exercise_date: On June 11, 2026, the Reporting Person received share options with respect to 77,778 shares under the SOIP. The share options will fully vest on June 10, 2027. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 10:50 UTC |
Zuegel MartinDirector · Interim CEO
|
GrantCommon Share | 33,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001651625-26-000010 · primary_doc.xml · nonDerivative · entry 1 Zuegel Martin · CIK 0001484988 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,408 F1 · price: On June 11, 2026, the Reporting Person received a restricted share unit grant of 33,136 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). F2 · balance_after: Comprised of 71,408 common shares underlying outstanding restricted share units. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 10:59 UTC |
AGUIAR-LUCANDER RENEEDirector
|
GrantShare Option (right to buy) · Derivative | 38,889 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001651625-26-000011 · primary_doc.xml · derivative · entry 2 AGUIAR-LUCANDER RENEE · CIK 0001591617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,889 Underlying: Common Share · 38,889 shares Expires 2036-06-10 F3 · derivative.exercise_date: On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 10:59 UTC |
AGUIAR-LUCANDER RENEEDirector
|
GrantCommon Share | 16,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001651625-26-000011 · primary_doc.xml · nonDerivative · entry 1 AGUIAR-LUCANDER RENEE · CIK 0001591617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,136 F1 · price: On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). F2 · balance_after: Comprised of 51,136 common shares underlying outstanding restricted share units. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 11:10 UTC |
Twyman Roy ErvinDirector
|
GrantShare Option (right to buy) · Derivative | 38,889 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001651625-26-000012 · primary_doc.xml · derivative · entry 2 Twyman Roy Ervin · CIK 0002117542 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,889 Underlying: Common Share · 38,889 shares Expires 2036-06-10 F3 · derivative.exercise_date: On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 11:10 UTC |
Twyman Roy ErvinDirector
|
GrantCommon Share | 16,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001651625-26-000012 · primary_doc.xml · nonDerivative · entry 1 Twyman Roy Ervin · CIK 0002117542 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,556 F1 · shares: On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). F2 · price: Includes 66,556 common shares underlying outstanding restricted share units. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 10:40 UTC |
Buetler MonikaDirector
|
GrantShare Option (right to buy) · Derivative | 41,667 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001651625-26-000009 · primary_doc.xml · derivative · entry 2 Buetler Monika · CIK 0002115138 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,667 Underlying: Common Share · 41,667 shares Expires 2036-06-10 F3 · derivative.exercise_date: On June 11, 2026, the Reporting Person received share options with respect to 41,667 shares under the SOIP. The share options will fully vest on June 10, 2027. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 10:40 UTC |
Buetler MonikaDirector
|
GrantCommon Share | 17,751 | $0.00 | $0.00 |
DisclosureSEC source: 0001651625-26-000009 · primary_doc.xml · nonDerivative · entry 1 Buetler Monika · CIK 0002115138 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,656 F1 · price: On June 11, 2026, the Reporting Person received a restricted share unit grant of 17,751 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). F2 · balance_after: Includes 70,656 common shares underlying outstanding restricted share units. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 10:31 UTC |
June Carl HowardDirector
|
GrantShare Option (right to buy) · Derivative | 38,889 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001651625-26-000008 · primary_doc.xml · derivative · entry 2 June Carl Howard · CIK 0002116422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,889 Underlying: Common Share · 38,889 shares Expires 2036-06-10 F3 · derivative.exercise_date: On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 10:31 UTC |
June Carl HowardDirector
|
GrantCommon Share | 16,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001651625-26-000008 · primary_doc.xml · nonDerivative · entry 1 June Carl Howard · CIK 0002116422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,556 F1 · price: On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). F2 · balance_after: Includes 66,556 common shares underlying outstanding restricted share units. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:25 UTC |
Pfeifer AndreaDirector · Chief Executive Officer
|
SaleCommon Share | 10,000 | $2.79 | $27,935.00 |
DisclosureSEC source: 0001651625-26-000007 · primary_doc.xml · nonDerivative · entry 1 Pfeifer Andrea · CIK 0001697107 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,820,288 F1 · price: The price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.825. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 1,921,005 common shares underlying outstanding restricted share units. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 16:39 UTC Amendment |
Pfeifer AndreaDirector · Chief Executive Officer
|
SaleShare | 10,000 | $3.14 | $31,425.00 |
DisclosureSEC source: 0001651625-26-000006 · primary_doc.xml · nonDerivative · entry 1 Pfeifer Andrea · CIK 0001697107 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,830,288 F1 · kind: This Form 4/A amends the Form 4 filed on April 16, 2026, inadvertently reporting in column 3 a purchase of 10,000 shares on behalf of the reporting person. This amendment corrects that filing to reflect that the reporting person sold 10,000 shares. F2 · price: The price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.19, inclusive. F3 · balance_after: Includes 1,921,005 common shares underlying outstanding restricted share units. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 15:10 UTC |
Pfeifer AndreaDirector · Chief Executive Officer
|
PurchaseShare | 10,000 | $3.14 | $31,425.00 |
DisclosureSEC source: 0001651625-26-000005 · primary_doc.xml · nonDerivative · entry 1 Pfeifer Andrea · CIK 0001697107 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,830,288 F2 · price: The price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.05 to $3.19, inclusive. F1 · balance_after: Includes 1,921,005 common shares underlying outstanding restricted share units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.